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Key points 
• The largest cohort of ambiguous leukemias to date reveals a better prognosis of children 
who started on lymphoid-directed treatment.  
• Myeloid type of primary treatment correlated with dismal outcomes in CD19pos 
leukemias. 
Abstract 
Despite attempts to improve the definitions of ambiguous leukemia (ALAL) during the last two 
decades, general therapy recommendations are missing. Herein, we report a large cohort of 
children with ALAL and propose a treatment strategy.  A retrospective multinational study 
iBFM-AMBI2012 on 233 cases of pediatric ALAL patients is presented. Survival statistics were 
used to compare the prognosis of subsets and types of treatment. Five-year event-free survival 
(5yEFS) of patients with acute lymphoblastic leukemia (ALL)-type primary therapy (80±4%) 
was superior to that of children who received acute myeloid leukemia (AML)-type or combined-
type treatments (36±7.2% and 50±12%, respectively). When ALL- or AML-specific gene fusions 
were excluded, 5yEFS of CD19
pos
 leukemia was 83±5.3% on ALL-type primary treatment 
compared to 0±0% and 28±14% on AML-type and combined-type primary treatment, 
respectively. Superiority of ALL-type treatment was documented in single-population mixed 
phenotype ALAL (using WHO and/or EGIL definitions), and in the bilineal ALAL. Treatment with 
ALL-type protocols is recommended for the majority of pediatric patients with ALAL, including 
cases with CD19
pos
 ALAL. AML-type of treatment is preferred in a minority of ALAL cases with 
CD19
neg
 and no other lymphoid features ALALs. No overall benefit of transplantation was 
documented and it could be introduced in some patients with a poor response to treatment. As 
no clear indicator was found for a change to the treatment type, this is to be considered only in 
cases with 5% blast or greater after remission induction. The results provide a basis for a 
prospective trial. 
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Introduction 
Cases with acute leukemias (AL) are typically diagnosed as belonging to either lymphoid or 
myeloid lineage. However, two to five percent of acute leukemia (AL) cases fulfill the definition 
of ambiguous lineage leukemia (ALAL). The following four different types of lineage ambiguities 
have been described: 1. single population mixed phenotype leukemias (MPAL; synonym 
biphenotypic AL), which share immunophenotypic features of lymphoblastic and myeloid AL 
(ALL and AML, respectively); 2. bilineal AL, in which two separate clones of different lineages 
coexist; 3. undifferentiated AL, in which the criteria of ALL and AML are not met due to a paucity 
of positive markers of any of the two; and 4. AL with an early switch to a different lineage, in 
which the phenotype of leukemic cells changes during treatment, usually during its early phases 
to a different lineage
1–3
. This type of ALAL is not part of the study, unless such switch is 
combined with one of the three aforementioned ALAL presentation features.  
Most of these leukemias fulfill one of the two international definitions of mixed phenotype 
leukemias (MPAL), both of which principally rely on flow cytometry. An older definition by the 
European Group for Immunophenotyping of Leukemia (EGIL) uses a spectrum of antigens 
weighted by their presumed significance
4,5
. A newer definition by World Health Organization 
(WHO) utilizes fewer antigens
6,7
 (Supplementary Table 1). In general, the prognosis of MPALs is 
slightly worse than that of the non-MPAL leukemias on the same type of treatment
8–11
.  
The spectrum of underlying genetic aberrations is wide. Whereas fusion genes with KMT2A 
(MLL) contribute to more myeloid or lymphoid phenotypes partly depending on the fusion 
partner
12
, other fusions are typically lymphoid with a few myeloid markers and only 
occasionally have a full ambiguous phenotype (ETV6/RUNX1) or analogically with myeloid 
lineage (RUNX1/RUNX1T1). These fusion genes, however, are present only in a minority of 
ALAL
9
, and the majority of ALAL is genetically heterogeneous. Next generation sequencing 
techniques are likely to discover not only further heterogeneity but also more recently identified 
recurrent genetic aberrations such as ZNF384 gene involving fusions, which occur especially in 
B-myeloid ALAL (Alexander et al, submitted and
13–15
). Mutations in TP53, which are generally 
more frequent in adult leukemias, were expectedly found mostly in adult ALALs
16
.  
The aim of the present study was to collect a detailed data on biological features, treatment and 
outcome of ALAL, allowing for setting up treatment recommendations that can be tested 
prospectively.  
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Patients and Methods 
Patient accrual 
Eighteen centers participated in the iBFM AMBI2012 study. These centers were located in 
Australia (single hospital), Austria, Brazil (single hospital), Czechia, Germany, Greece (single 
hospital), Israel (single hospital), Italy, Netherlands, the NOPHO group (representing Denmark, 
Estonia, Finland, Norway, Sweden, Iceland and Lithuania), PINDA (Chile), Poland, SAHOP 
(Argentina), Slovakia, St. Jude Children's Research Hospital and Baylor College of Medicine (USA, 
two institutions), Ukraine and the United Kingdom. Each center supplied data to a web-based 
database on consecutive children. The periods of referral differed between the centers and 
lasted 1 to 12 years, except for Greece, which reported three isolated cases (Supplementary 
Table 2). Patients diagnosed before 2002 or after June 1, 2015 were excluded from this study. 
The fulfillment of the inclusion criteria was then verified by three of the authors (VdH, JiS and 
OH). Except when excluded patients are explicitly mentioned, all analyses address included 
patients only.  
Inclusion criteria 
Patients with acute leukemia diagnosed or referenced in one of the participating centers within 
the study period before 18 years of age were considered for analysis. Definition of a single 
population biphenotypic/mixed lineage leukemia or bilineal leukemia or undifferentiated 
leukemia was fulfilled. For single population ALAL, the immunophenotypic criteria of EGIL 
and/or WHO were met. Cases with more than one significant population, each belonging to a 
different lineage, were considered bilineal. Blast populations which did not fulfill the criteria of 
B, T or myeloid lineages were considered undifferentiated. Subsequently, we excluded patients 
who suffered from a genetic disease that is considered as predisposing for leukemia. Lastly, we 
excluded patients who received only palliative treatment or other treatment not considered as 
ALL-type, AML-type or combined-type (Supplementary Table 3). 
Statistics 
For event free survival (EFS) calculations, the uncensored event was death of any cause, relapse 
of leukemia, and secondary malignancy. The censoring times included time to a treatment type 
change unless we explicitly mention that treatment changes are disregarded. In other instances, 
censoring times reflected the end of follow up without an event. For univariate comparisons of 
EFS, log-rank (Mantel Cox) test was used. For the analysis of possible benefit of stem cell 
transplantation (SCT), a delayed entry statistics was applied, in which all events (deaths, 
relapses or secondary malignancy onsets) preceding the median time to SCT for the analyzed 
subcohort were considered censored times.  
For multivariate Cox regression, the following variables were considered: referring center, age, 
sex, white blood cells per L (WBC), CNS infiltration, fulfillment of WHO/EGIL criteria, 
categorization to single population/bilineal/undifferentiated, estimate of lineage by AIEOP/BFM 
Flow
17
, positivity of KMT2A/AFF1, lineages involved using EGIL criteria or using WHO criteria, 
frequency of blasts, and positivity of CD1a, CD2, CD3, intracellular (i)CD3, CD5, CD7, CD8, CD10, 
CD117, CD11c, CD13, CD14, CD15, CD19, CD20, CD22, iCD22, CD24, CD33, CD64, CD65, iCD79a, 
iIgM, iLysozyme, iMPO, TCRab, TCRgb, and iTdT. Factors with no correlation with the outcome in 
univariate pre-assessment (p>0.2) were considered irrelevant, leaving WBC and positivity of 
KMT2A/AFF1, CD2, CD10, CD11c, CD22, iCD22, CD24, CD64, iMPO, and iTdT included in the 
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analysis for ALL treated patients. For AML treated patients, the following factors were 
considered relevant and included in the analysis: Age at diagnosis, WBC and positivity of 
KMT2A/AFF1, CD2, iCD3, CD7, CD14, CD19, CD22, iCD79a, and iMPO. 
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Results 
Characteristics of the included patients 
In total, data on 274 patients were available. Consort diagram of the entire study is in Figure 1. 
Of these, 233 cases fulfilled the inclusion criteria. The exclusion of non-eligible cases (n=41) did 
not noticeably affect the 5 year EFS of the entire cohort (62±3.6% and 65±3.8% before and after 
the exclusion, respectively). The predisposing genetic diseases that resulted in exclusion from 
the cohort (n=8) comprised Fanconi anemia (n=2), Down syndrome (n=4) and GATA2 mutations 
(n=2). Patients excluded for not having received or not having been assigned to any type of 
therapy (n=4) or with a missing info on primary therapy (n=3) partially overlapped with the 
ones excluded for predisposing genetic features. The remaining part of the article describes only 
the included patients. Demographic and diagnostic information is listed in Table 1, together with 
the primary chemotherapy. In total, 176 patients had single population ALAL, 45 had bilineal 
and 12 had undifferentiated leukemia. Of the single-population ALAL, 103 fulfilled WHO and 
EGIL definitions, 42 fulfilled EGIL only and 31 fulfilled WHO only. Distribution of cases into 
genetic categories demonstrates the heterogeneity of ALAL and the correlation with the 
physicians’ choice of primary treatment type or with lineages involved (Supplementary Table 4).  
Selection of the treatment type 
Due to the specific nature of ALAL, various treatment protocols or experimental therapies have 
been applied. Supplementary Table 5 lists the different choices of the initial therapy.  
The outcome of patients who started on ALL-type treatment was superior (5 year EFS, 80±4.0%) 
compared to the outcome of patients who started on AML-type or on a combined-type 
(ALL/AML) treatment (5 year EFS, 36±7.2% and 50±12%, respectively; Figure 2). No significant 
prognostic difference was observed between AML- and combined-type primary therapies. The 
treatment toxicity was in general relatively high, accounting for 18/63 deaths, seemingly evenly 
distributed between ALL-, combined- or AML-type primary therapy (7.4, 8 and 8.3% patients on 
the respective primary treatment). In total, 69 children underwent SCT and 20 of them (29%) 
died - 4 patients (5.8%) from toxicity and 16 (23%) from leukemia progression.  
Genetic categories 
The genetic categories of the patients document a diversity of ALAL. The genetic findings of the 
patients in the study are shown in correlation to the primary type of therapy and to the type of 
ambiguity in Supplementary Table 4.  
Prognostic impact of ambiguity types 
Patients with bilineal ALAL (Figure 3) fared better on ALL compared to AML therapy (5 year 
EFS, 65±12% and 14±13%) and in general fared worse than single-population ALAL (5 year EFS, 
84±4.2% and 43±8.9 %, for ALL and AML therapy, respectively). Supplementary Figure 1 
demonstrates that the better prognosis on ALL-type primary therapy holds true for ALAL 
defined by the EGIL criteria only and for ALAL defined by WHO criteria or both. 
Typical ALL- or AML-specific gene fusions 
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As patients with molecular genetic findings that are considered to be unequivocally ALL 
(ETV6/RUNX1, or TCF3/PBX1) or AML (RUNX1/RUNX1T1, PML/RARA, or CBFB/MYH11)
12,18
 
should be guided as such in treatment recommendations, we have not included these patients 
into the subsequent analyses. In patients with BCR/ABL1 fusion, ALL-type of treatment with 
Tyrosine kinase inhibitors are indicated
19
 and BCR/ABL1
pos
 cases were also excluded from 
further analyses. Typically, TCF3/PBX1 leads to non-ambiguous ALL and CBFB/MYH11 leads to 
non-ambiguous AML. In line with this rule, no patient in our study was identified with 
TCF3/PBX1 or CBFB/MYH11. In total, 31 (13%) patients had one of the above named gene 
fusions. For the remaining 202 (87%) patients, we searched for the most significant parameters 
that would correlate with prognosis.  
Multivariate analysis pointed to CD19 positivity 
Among the patients without the gene fusions specified in the previous paragraph, 124 and 53 
cases received ALL and AML types of treatment, respectively. For each of these major types of 
treatment separately, a multivariate Cox regression analysis was performed. Of all factors 
considered (see Methods for variable list and their univariate pre-assessment), WBC and iMPO 
were prognostically significant in ALL-type primary treatment and WBC and CD19 were 
prognostically significant in AML-type primary treatment (Table 2 and Table 3, respectively).  
After identifying factors associated with differences in risks of events within one type of 
treatment, we searched for the ones that correlated with the most significant prognostic 
difference between ALL- and AML-types of therapy (Supplementary Table 6). Out of these 
parameters, the most striking difference between ALL- and AML-type of primary therapy was 
found among CD19
pos
 cases (Figure 4a and 4c). Among patients with positivity of CD19 (which 
included a positivity or a partial positivity in at least one blast population in cases with bilineal 
ALAL) the outcome strongly correlated with type of treatment. Whereas the 5-year EFS of 
children who received ALL type primary therapy was 83±5.3%, the 5-year EFS of children who 
started with AML or combined type of treatments was inferior (0±0 % and 28±14%, both p 
values <0.0001). After AML type primary therapy, no patient was alive and without an event 
beyond 1.4 years after the diagnosis. We thus consider cases with CD19 indicated for a non-AML 
primary treatment. Details on CD19
pos
 cases with AML-type primary treatment are described in 
Supplementary Information 1. Among patients who started on a combined type treatment, there 
was a high proportion of KMT2A/AFF1
pos
 ALAL (Supplementary Table 4), which largely drives 
the poorer prognosis of this subset. Among KMT2A/AFF1
neg
 cases with CD19, the 5-year EFS did 
not differ between children with a combined-type treatment (71±17%, n=8) and ALL-type 
treatment (84±5.2%, n=84; p=0.38). 
Primary treatment options for CD19
neg
 patients  
If we consider patients with above-listed gene fusions, and/or with CD19
pos
 blasts assigned to 
recommended primary treatments, 33 % of patients remain to be addressed (76 of 233 in our 
cohort). The primary therapy was of ALL-, combined- and AML- type in 35 (46%) nine (12%) 
and 32 (42%) cases, respectively. In total, 18 events occurred in this subset of patients with an 
ALL -, combined- and AML-type primary therapy (four, one and 13 events, respectively).  
The two main types of primary therapy (ALL- and AML-type) were compared for CD19
neg
 cases 
(n=67). As we sought to find a parameter that would positively define a biologic subset, we 
analyzed the impact of the remaining (after exclusion of CD19) antigens that define lymphoid 
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involvement both in the EGIL and in the WHO classification. This means, cases were selected 
with positive CD7 and CD3 (intracellular or surface) or with at least 2 positive antigens of CD10, 
intracellular CD79a, and CD22 (intracellular or surface). This selected subcohort had a very good 
outcome on either ALL- or combined-type primary therapy (Figure 4b and 4d).  
Among the remaining 10 patients, five children fulfilled criteria for undifferentiated leukemia. 
Although the number of patients was too low to make reliable conclusions, the ALL-type primary 
treatment appeared particularly inefficient: of the three patients on ALL-type primary 
treatment, the type of treatment was changed between days 15 and 19 of treatment and both 
died before three months after diagnosis. The third patient died two years after diagnosis. In 
contrast, four of five patients who received AML-type primary treatment were alive, although 
only one of them in CR1. The treatment was changed from AML-type in two patients at days 15 
and 34 of treatment). Finally, both patients on combined-type treatment remained on it and 
were in the CR1.  
 
Major changes of treatment 
In 29 patients, the treatment type (ALL/combined/AML) was changed after 8 to 126 days of 
therapy (median 32 days, Supplementary Figure 2). The reasons for these treatment type 
changes mostly reflected response to the primary treatment. Although – as expected – the 
outcome of patients whose type of treatment changed was poorer, some of the patients whose 
treatment type changed were brought to durable remission in each of the types of primary 
treatment.  
Another major treatment factor was SCT. In total, 69 patients underwent SCT, and 58 of them 
were transplanted in the first complete remission (CR1). Using a delayed entry survival analysis, 
no significant prognostic benefit could be demonstrated in ALL-, AML- or combined-type of 
primary treatment (Figure 5).  
We then analyzed specifically patients with a high leukemia load at the end of induction (ALL-, 
AML- or combined-type primary treatment). In total, 31 patients had 5% leukemic cells or 
greater. This relatively low number of patients did not allow separation by type of primary 
treatment. Of the 31 patients, 12 underwent SCT (irrespective of the remission status at the time 
of SCT). The 5y EFS of these transplanted children was 83±15%, compared to 29±16% among 
non-transplanted patients (p>0.05); in a delayed-entry analysis, the 5y EFS were 83±15% and 
36±19%, respectively (p>0.05). 
 
Response to ALL treatment and when to consider treatment changes 
Patients, who started on ALL-type therapy would be indicated for a treatment change if their 
estimated outcome was poorer on a continued ALL treatment than on the changed treatment 
type. Such a poor response predictor could be anticipated especially if the ALAL patients with 
poorer response to initial treatment have a markedly poorer prognosis than similar patients 
with non-ambiguous ALL. Therefore, we evaluated the proportion and EFS of ALAL patients with 
poor treatment response. Among CD19
pos
 and CD19
neg
 ALAL cases, the proportion of patients 
with a poorer leukemia clearance was 25% and 50% at day 8 (poor prednisone responders, PPR, 
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outcome in Figure 6), 32% and 60% at the end of induction (MRD at or above 0.1%, outcome in 
Supplementary Figure 3a-b and e-f), and 13% and 10% at week 12 (MRD at or above 0.01%, 
outcome in Supplementary Figure 3c-d and g-h) respectively.  
By definition, a poorer blast clearance at day 8 is found in PPR. The 5y EFS of CD19
pos
 PPR with 
ALAL was 47±14%, which appears inferior than that of non-ambiguous pB ALL (68±4.6%
20
). As 
the principal question was whether the type of treatment should be changed, we analyzed the 
number and outcome of children whose type of treatment changed at any time after PPR status 
was set. Of the 23 CD19
pos
 ALAL PPRs, the treatment type was changed in 11 and remained ALL-
type in 12, leading to continued CR1 in four and six cases, respectively. The 5y EFS of CD19
neg
 
PPRs was (90±9.5%), definitely not inferior than that reported in the non-ambiguous T ALL 
(63±5.7%
20
).  
At the end of induction, the EFS of CD19
pos
 and CD19
neg
 cases with MRD 0.1% or higher was 
60±13% and 79±11% (Supplementary Figure 3a-b), respectively, which appears to show non-
inferior outcome to that reported for non-ambiguous ALL cases (cumulative incidence of 
relapses, 36±3.6%, and 32±3.6%, for pB at five years
21
 and T ALL at seven years
22
, respectively) 
and possibly reflects increased treatment intensities in the MRD higher risk patients treated by 
contemporary protocols.  
At week 12, the 5y EFS of CD19
pos
 cases with MRD 0.01% or higher was 50±19% but both 
CD19
neg
 cases with MRD 0.01% or higher died, one from toxicity and one from leukemia 
(Supplementary Figure 3c-d). Whereas the data of CD19
pos
 ALAL cases do not indicate a marked 
difference of non-ambiguous pB ALL with high MRD
23
, the grim prognosis of the two CD19
neg
 
cases calls for more data. 
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Discussion 
Diagnosis of ALAL 
We present the largest study to date on childhood ALAL, involving children with three types of 
ambiguity. Keeping these patients together in one cohort allows for overlapping cases, e.g., it 
depends on the investigator whether they consider cells with distinct phenotype as two separate 
populations (and thus a bilineal leukemia) or they consider one leukemic population that 
differentiates into two phenotypic states. We have shown previously that even quite 
phenotypically distinct populations might result from one clone
24
.  
Before the first attempts to standardize the ALAL definitions by immunophenotyping in the 
1990s, the value of morphological examinations was also investigated
25
. While ALAL typically 
presents with ambiguous morphological features, there are cases with typical ALL or AML 
picture. In an early study by Pui et al
25
, which used morphologic and cytochemical diagnostic 
criteria for treatment selection, two of the four non-responders to AML-type treatment later 
responded to ALL-type therapy. However, morphology was not in focus of more recent studies 
including this one.  
Optimal therapy for ALAL 
So far, treatment recommendations are mostly based on scarce observations or on assumptions 
based on the biological similarities of leukemic cells to physiological hematopoiesis. In 
physiological granulocytic development, MPO is a prominent molecule and serves as a 
traditional marker of myeloid differentiation. However, its expression was documented in ALL 
cells on mRNA and on protein levels
26
 and although it was missing in more mature B or T cells, it 
was found also in mRNA of sorted physiological preB cells (recalculated data of reference
27
). 
Moreover, there is no evidence that MPO expression is directly connected to a better response to 
AML-type of therapy. In fact, cases of MPO
pos
 leukemia well responding to ALL-type of therapy 
are documented in the literature
26,28
 and in this study. Given the variability of MPO expression, it 
is not surprising that there has been a debate over the cutoff for the diagnostic MPO positivity
29–
31
. 
This study documents the diagnostic heterogeneity of ALAL and demonstrates that the 
therapeutic approaches vary. These results, together with the retrospective nature of our study, 
led us to interpret our data with caution. We observed a superior outcome of children treated 
with ALL-type therapy which is in line with previous studies
8,9,32–35
. This finding should not 
automatically imply that ALL-type therapy is superior for any subset of ALAL. However, the 
striking failure of AML-type therapy to cure any child with CD19
pos
 leukemia in absence of AML-
specific gene fusions leads us to recommend other types of chemotherapy in this relatively large 
subset of ALAL. However, without a prospective study, we are unable to estimate the prognosis 
of these ALAL patients on ALL-type treatment. For the remaining 33% of patients, the support 
for our recommendation is less clear, and the ultimate answer could only come after being 
tested prospectively. We have established an international platform, which has allowed testing 
the prognosis of children with ALAL treated according to predefined rules.  
Given that the phenotype of ALAL is in between classical ALL and AML, it has always been 
tempting to speculate that these leukemias would respond best to therapy, which would 
comprise elements of both ALL and AML types of treatment. This speculation assumes that what 
has been proven empirically for “pure” ALL or AML would analogically hold true for borderline 
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cases. One problem is that this assumption might be wrong. Second, both ALL- and AML-types of 
treatment are close to maximum tolerable intensity. Therefore, by intending to combine these 
treatments, we either compromise their efficacy or increase the risk of toxicity beyond 
acceptable margins.  
Primary treatment algorithm 
Collectively, the data leads to an algorithm, details of which can be tested prospectively (Figure 
7). After addressing ALL- and AML-specific fusions (13% of our cohort), positivity of CD19 
should be considered. Due to the dismal outcome of CD19
pos
 cases on AML-type primary 
treatment, this primary treatment type is not recommended. Although the EFS of CD19
pos
 
patients on combined-type primary therapy was significantly poorer than that of the patients on 
ALL-type primary treatment, this difference was largely driven by a high proportion of 
KMT2A/AFF1
pos
 cases; among KMT2A/AFF1
neg
 cases, the outcome corresponding to the 
combined-type treatment is not different from the outcome on ALL-type primary treatment. 
Thus, combined-type primary treatment is a possible alternative for CD19
pos
 ALAL. For the 
CD19
neg
 patients, the bases for recommendations were less straightforward. In presence of 
lymphoid markers, the outcome on ALL-type primary therapy was excellent, which should be 
considered. However, a minority of children on AML-type primary therapy had an outcome 
similar to that of non-ambiguous AML, leaving this option open of AML-type therapy for cases 
with additional myeloid features. Very rarely, ALAL presented without CD19 or the listed 
lymphoid features, and the outcome was poor, especially on ALL-type treatment, making the 
other two types of primary treatment preferred. Altogether, these treatment recommendations 
should be tested prospectively in the setting of multidisciplinary leukemia diagnostics.  
Changing the treatment type, transplantation 
In addition to the selection of the primary treatment type, another key question is whether and 
when to change the type of treatment. The outcome of ALAL patients with a poorer blast 
clearance at day 8 (CD19
neg
 PPRs) or at the end of induction (both CD19
pos
 and CD19
neg
 cases) 
was not inferior to what is expected for non-ambiguous ALL. Although CD19
pos
 PPRs among 
ALAL do appear to have a lower prognosis than analogous non-ambiguous ALL cases, in half of 
them the type of treatment changed after day 8; while this change did not bring a clear benefit in 
a low number of patients, a similarly low number of patients stayed on ALL-type of therapy. 
Notably, our data shows that proportion of PPRs is higher (23 of 92 (25%) patients with CD19
pos
  
ALAL and 15 of 30 (50%) patients with CD19
neg
 ALAL on ALL-type of treatment with known 
prednisone response) than in non-ambiguous ALL (6.4% and 34% in BCP ALL and T ALL, 
respectively)
20
. Children who remain on ALL type of treatment should thus often be treated in 
high risk strata.  
For evaluation of SCT benefit specifically among patients with high leukemia burden at the end 
of induction, the number of patients in our cohort was limited and the possible benefit was not 
significant. With all the limitations, our observation points to the fact that patients with very 
poor response to induction treatment may be transplanted and rescued. Major treatment type 
modifications are thus to be considered only in children who do not achieve CR1 by the end of 
induction. Such modifications comprise either SCT or, after re-evaluation of blasts’ phenotype, 
change of the treatment type. The possibility to transplant children with poor treatment 
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response is in line with a recent smaller study, which find a benefit of SCT in adult ALAL, 
although not using delayed-entry analysis
32
.    
Conclusion 
In summary, a multicenter international study was used for outlining the treatment 
recommendations for children with ALAL. These recommendations should be tested 
prospectively in a multinational study, and eventually, each patient with ALAL would be 
assigned to their optimal treatment.   
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Legends  
Figure Legends 
Figure 1. Flow chart. Rectangles contain selection criteria in each step followed with a number of 
patients in parentheses. Tables or Figures mentioned next to each rectangle depict all patients from the 
respective node unless a selection is specified in a footnote.  
Figure 2. Outcome of patients with ambiguous lineage leukemia by the primary type of 
treatment. ALL - acute lymphoblastic leukemia; AML - acute myeloid leukemia. Log-rank (Mantel 
Cox) statistical test was used. (A) event free survival; (B) overall survival. 
Figure 3. Outcome of patients with ambiguous lineage leukemia (ALAL) on different treatment 
types. Single popuplation ALAL vs. bilineal ALAL. ALL - acute lymphoblastic leukemia; AML - 
acute myeloid leukemia. Log-rank (Mantel Cox) statistical test was used. (A) event free survival; (B) 
overall survival. 
Figure 4. Outcome of children with CD19pos ambiguous lineage leukemia (ALAL) and CD19neg  
ALAL with other lymphoid-specific antigens by the type of primary therapy. Patients without 
ETV6/RUNX1, RUNX1/RUNX1T1, PML/RARA or BCR/ABL1 gene fusions. ALL - acute 
lymphoblastic leukemia; AML - acute myeloid leukemia. Log-rank (Mantel Cox) statistical test was 
used. (A) Event free survival of CD19pos ALAL; (B) Event free survival of CD 19neg ALAL with other 
lymphoid-specific antigens; (C) Overall survival of CD19pos; (D) Overall survival of CD 19neg ALAL 
with other lymphoid-specific antigens. Other lymphoid-specific antigens are listed in Results. 
Figure 5. Outcome of ambiguous lineage leukemia patients transplanted in the first complete 
remission compared to other patients. In each type of primary treatment, events occurring prior to 
the median time to transplant were neglected. SCT - stem cells transplantation; CR1 - first complete 
remission. Log-rank (Mantel Cox) statistical test was used. (A) acute lymphoblastic leukemia (ALL) 
treatment type - event free survival ; (B) combined type of treatment - event free survival; (C) acute 
myeloid leukemia treatment type (AML) - event free survival; (D) ALL treatment type - overall 
survival; (E) combined type of treatment - overall survival; (F) AML treatment type - overall survival. 
Figure 6. Outcome of ambiguous lineage leukemia patients in relation to their response to 
prednisone. Log-rank (Mantel Cox) statistical test was used. (A) CD19pos cases event free survival; 
(B) CD19neg cases event free survival; (C) CD19pos cases overall survival; (D) CD19neg cases overall 
survival. 
Figure 7. Treatment recommendation algorithm. After each decision node, number (percentage) of 
patients still to be categorized is given. Note that the algorithm shows a recommendation to be tested 
prospectively and does not refer to the way how patients in this study were treated. Numbers 
(percentages) include all 233 patients in the study with confirmed inclusion criteria. Primary types of 
treatment: ALL - acute lymphoblastic leukemia; AML - acute myeloid leukemia; TKI - tyrosine kinase 
inhibitors; i (as a prefix) - intracellular or surface; pos - positive (or partly positive); neg – negative. 
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Table Legends 
Table 1. Patient characteristics and primary choice of treatment. ALL - acute lymphoblastic 
leukemia; AML- acute myeloid leukemia. WBC – white blood cell count, 109 per L, CNS leu – 
leukocyte including pathological cells presence in cerebrospinal fluid at diagnosis. Age group – age at 
diagnosis, in years (y). CR1(2) – first (second) complete remission of leukemia. 
Table 2. Multivariate Cox regression analysis of risk factors after ALL -type of primary 
therapy. Results of the multivariate Cox regression analysis of event-free survival in cases without 
evidence of a preexisting genetic disease or the specified gene fusions (ETV6/RUNX1, 
RUNX1/RUNX1T1, PML/RARA, or BCR/ABL1) primarily treated with ALL- type therapy. For the 
treatment type, 11 factors that withstood the univariate prescreening (listed in Methods) were included 
in the model. LCL, UCL – lower and upper limits of a confidence intervals, respectively. 
Table 3. Multivariate Cox regression analysis of risk factors after AML -type of primary 
therapy. Results of the multivariate Cox regression analysis of event-free survival in cases without 
evidence of a preexisting genetic disease or the specified gene fusions (ETV6/RUNX1, 
RUNX1/RUNX1T1, PML/RARA, or BCR/ABL1) primarily treated with AML- type therapy. For the 
treatment type, 11 factors that withstood the univariate prescreening (listed in Methods) were included 
in the model. LCL, UCL – lower and upper limits of a confidence intervals, respectively. 
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Table 1 
 Primary protocol Type of ambiguity 
ALL-type 
N (%) 
combined 
type 
N (%) 
AML-
type 
N (%) 
Chi-
square p-
value* 
Bilineal 
 
Single 
population 
undifferentia
ted 
Chi-
square 
p-value* 
Total  148 (100) 25 (100) 60 (100)  45 (100) 176 (100) 12 (100)  
Sex 
female 62 (42) 12 (48) 30 (50) 
0.53 19 (42) 79 (45) 6 (50) 0.88 
male 86 (58) 13 (52) 30 (50) 26 (58) 97 (55) 6 (50) 
WBC 
below 20 88 (59) 8 (32) 24 (40) 
0.002 
19 (42) 96 (55) 5 (42) 
<0.0001 20 to 100 42 (28) 7 (28) 18 (30) 6 (13) 57 (32) 4 (33) 
100 or above 18 (12) 10 (40) 18 (30) 20 (44) 23 (13) 3 (25) 
Age group 
infant 1 (0.68) 13 (52) 8 (13) 
<0.0001 
8 (18) 11 (6) 3 (25) 
0.087 
1 to <6y 50 (34) 4 (16) 15 (25) 10 (22) 57 (32) 2 (17) 
6 to <11y 45 (30) 4 (16) 11 (18) 12 (27) 44 (25) 4 (33) 
11 to <18y 52 (35) 4 (16) 26 (43) 15 (33) 54 (31) 3 (25) 
CNS leu 
no 133 (90) 15 (60) 47 (78) 
0.0001 
30 (67) 156 (89) 9 (75) 
0.0002 yes 10 (6.8) 9 (36) 10 (17) 14 (31) 14 (8) 1 (8.3) 
not known* 5 (3.4) 1 (4) 3 (5)  1 (2.2) 6 (3.4) 2 (17) 
 
Type of ambiguity 
bilineal  24 (16) 9 (36) 12 (20) 
0.048 
N/A N/A N/A 
N/A single population 119 (80) 15 (60) 42 (70) N/A N/A N/A 
undifferentiated 5 (3.4) 1 (4) 6 (10) N/A N/A N/A 
Follow up status 
alive with leukemia 0 (0) 0 (0) 3 (5) 
<0.0001 
0 (0) 3 (1.7) 0 (0) 
0.0001 
CR1 115 (78) 14 (56) 22 (37) 21 (47) 126 (72) 4 (33) 
CR2 or higher 3 (2) 3 (12) 6 (10) 1 (2.2) 9 (5.1) 2 (17) 
death from leukemia 17 (11) 6 (24) 22 (37) 12 (27) 28 (16) 5 (42) 
death from toxicity 11 (7.4) 2 (8) 5 (8.3) 9 (20) 8 (4.5) 1 (8.3) 
death from unknown reason 1 (0.7) 0 (0) 1 (1.7) 2 (4.4) 0 (0) 0 (0) 
lost to follow up* 1 (0.68) 0 (0) 1 (1.7)  0 (0) 2 (1.1) 0 (0) 
 
*
 For Chi-square calculations, unknown items are not considered. 
 
Table 2 
 
 
 
Parameter Hazard ratio LCL UCL p 
WBC 1·01 1·005 1·02 0·0004 
iMPO 0·27 0·090 0·83 0·022 
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Table 3 
 
 
Parameter Hazard ratio LCL UCL p 
WBC 1·005 1·002 1·007 0·002 
CD19 3·17 1·39 7·21 0·006 
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1Fig 3 includes single population (119 ALL treatment, 42 AML treatment) and bilineal (24 ALL treatment, 12 
AML treatment) ALALs, the remaining  cases are undifferentiated (5 ALL treatment, 6 AML treatment)
2Supp Fig 1 includes single population ALALs (119 ALL treatment, 42 AML treatment)
3Fig 6 includes patients with known prednisone response (92 CD19pos, 30  CD19neg)
4Supp Fig 3 includes patients with known MRD (EOI: 94 CD19pos, 30 CD19neg; week 12: 82 CD19pos, 20 CD19neg)
5Supp Tab 6 analysis was done only from data of AML- (n=53) or ALL- treated patients (n=124)
Figure 1
patients  referred (274)
inclusion criteria confirmed
(233)
3Fig 6
4Supp Fig 3
Fig 2
Fig 5
Supp Fig 2
1Fig 3
2Supp Fig 1
CD19neg (76)
other (10)
presence of ALL- or AML-
specific fusions (31)
CD19 unknown (1)
inclusion criteria not confirmed
(41)
primary treatment combined-
type (25)
primary treatment AML- type 
(60)
CD19 unknown (1)
CD19neg (38)CD19pos (109)
primary treatment ALL- or 
AML-type (208)
primary treatment ALL- type 
(148)
CD19 known (147)
CD19pos (125)
(i)CD3 and CD7
or
At least 2 of CD10, CD79a, 
(i)CD22 (66)
no presence of ALL- or AML-
specific fusion (202)
CD19 known (201)
Fig 4A,4C
Fig 4B,4D
Table 1
Supp Tab 4
Supp Tab 5
5Supp Tab 6
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